Updates on the efficacy of new and emerging therapies for myasthenia gravis (MG) presented at the American Association of Neuromuscular and Electrodiagnostic Medicine 2025 Annual Meeting are discussed ...

Generalised myasthenia gravis is a rare, long‑term autoimmune condition. It causes muscle weakness and extreme tiredness, and can affect breathing, speech, swallowing, eyesight and movement. Symptoms ...

Gravis, a provider of engineered dry bulk transportation packaging solutions, has announced its acquisition of Western Packaging Solutions, a Montreal, Canada-based distributor of flexible ...

A growing number of new treatments for myasthenia gravis (MG) are changing how doctors manage the disease and offering new options for people whose symptoms aren’t fully controlled. In recent years, ...

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. The fatigue associated with MG is often described as “fatigable weakness,” ...

Expanding its capabilities in several end markets Gravis Global Products has announced the acquisition of Procon Pacific, a distributor of flexible intermediate bulk containers (FIBCs) and BOPP woven ...

Myasthenia gravis (MG) or its treatments may lead to urinary symptoms. Studies suggest a link between overactive bladder symptoms and a common MG medication called pyridostigmine. Urinary symptoms in ...

Acupuncture may help reduce symptoms and improve overall quality of life when used as a complementary therapy for myasthenia gravis (MG), but further research is needed to explore its effectiveness.

The FDA has approved the CD19+ B-cell targeted therapy inebilizumab-cdon (Uplizna, Amgen) for the treatment of adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine ...

Since late 2021, a bevy of targeted generalized myasthenia gravis therapies has crossed the regulatory finish line in the U.S., beginning with argenx’s FcRn blocker Vyvgart four years ago and most ...